Clinical Trial Search

Primary: Differences in Histologic Alterations in Rash Caused by Lapatinib, a Dual HER1/2 Inhibitor (HER1/2i), and the Single HER1 Inhibitors (HER1i) Cetuximab, Erlotinib,and…

Primary: Overall Incidence of Rash — 84; 84; 82 percentage of participants — p=0.8769

Primary: Percentage of Participants Who Develop Skin Rash — 60.0; 69.2; 73.1 percentage of participants — p=0.481

Primary: Duration of RAS Lesions — 1.57 weeks

Primary: Cumulative Irritation Score of RUT058-60 Hypochlorous Acid Solution (106 mg/L) on Healthy Human Skin — 1.00; 2.46; 1.34; 0.58 units on a scale

Primary: Skin Texture — 1.8; 0.5; 0 Score on a scale

Primary: Proportion of Patients With Chronic Hand Dermatitis Improvement as Assessed by Investigators Global Assessment — 0.53 proportion of participants

Primary: Percentage of Participants With Erlotinib Associated Rash Stratified by Severity Grade at Week 2 — 11; 22; 0; 33 percentage of participants

Primary: Number of Patients Reporting a Grade 2+ Adverse Event Attributed to Spironolactone (Study I) — 0; 0 Participants

Primary: Erythema at the Patch Test Site is Evaluated for Each Participant — 0.00; 0.59; 0.00 erythema score

Primary: Percentage of Participants Who Achieve a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) of the Head and Neck Region at Week 4 — 17.4; 37.0…

Primary: Number of Participants With Investigator Global Assessment of 0 or 1 at Week 4 — 20 Participants

Primary: Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy…

Primary: Absolute Change From Baseline in Total Lesion Score for All Treatable Psoriatic Lesions to Day 84 — -1.07; -2.25; -2.47; -2.27 score on a scale — p=0.0041

Primary: Number of Patients in Which the PI Observed a Notable Difference in the Number of Lesions — 4; 4 participants